Alkermes
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Alkermes sits in the top decile of US sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count).
Alkermes: 66 sponsored US clinical trials, 6 recruiting.
Alkermes sponsors 66 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 58 completed. 28 of these trials are in Phase 3-4 (later-stage) and 36 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 7 trials.
Top-decile sponsor footprint
Alkermes ranks in the top decile of sponsors by registered trial count (#314 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
58 of 60 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (96.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
66 total, page 2 of 2
ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
NCT01418092
ALK21-025: Vivitrol's Cost and Treatment Outcomes Registry
NCT01422837
ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC)
NCT01382797
ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine
NCT01366001
ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD
NCT01381107
A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration
NCT01453374
ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder
NCT01098435
ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC)
NCT01100151
ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence
NCT00981617
Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery
NCT00945763
ALK21-021: A Safety Study of Medisorb® Naltrexone (VIVITROL®) Administered to Health Care Professionals
NCT00834080
ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD
NCT00801684
ALK33-001: A Study of RDC-0313 Administered to Healthy Adults
NCT00800319
ALK29-002: A Study of Baclofen Formulations in Healthy Adults
NCT00802035
ALK21-018: Effects of Medisorb® Naltrexone (VIVITROL®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults
NCT00511836
The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis
NCT00002316
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 22 |
| Phase 2 | 14 |
| Phase 3 | 25 |
| Phase 4 | 3 |
What is open in the Alkermes pipeline
6 recruiting of 66 indexed (9% open); 58 completed (88%).
Phase mix: 28 late (III/IV) vs 36 early (I/II) (balanced across stages).
Top condition: Schizophrenia (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Alkermes: open-pipeline peers nationwide
Peers matched on 66 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Alkermes sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 66 trials (± recruiting share)
- Cornell University · 66 trials · 15% recruiting
- New Mexico Cancer Research Alliance · 66 trials · 6% recruiting
- University of Kansas · 66 trials · 8% recruiting
- Prisma Health-Upstate · 67 trials · 9% recruiting
Sponsors near 9% open enrollment (± trial volume)
- DBV Technologies · 9% recruiting · 11 trials
- Florida Gulf Coast University · 9% recruiting · 11 trials
- Genfit · 9% recruiting · 11 trials
- HiberCell · 9% recruiting · 11 trials
Related
What to do with this Alkermes page
66 registered trials is a research-attention snapshot, not an endorsement of Alkermes or any single study.
- 6 of Alkermes's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Alkermes studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Alkermes pipeline card: 66 registered trials from official public datasets.Report a data error.